Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin in Parkinson's Disease Psychosis
NCT00658567Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Mar 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of pimavanserin in Parkinson's disease (PD) (3 arms), sponsored by Acadia Pharmaceuticals. Primary endpoint: Scale for the Assessment of Positive Symptoms - Hallucinations and Delusions at Day 42. Started Mar 2008; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00658567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658567.